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Abstract
 
In the nonobese diabetic (NOD) mouse model of type 1 diabetes, the immune system recog-
nizes many autoantigens expressed in pancreatic islet 
 
  
 
cells. To silence autoimmunity, we used
dendritic cells (DCs) from NOD mice to expand CD25
 
  
 
CD4
 
  
 
suppressor T cells from
BDC2.5 mice, which are specific for a single islet autoantigen. The expanded T cells were
more suppressive in vitro than their freshly isolated counterparts, indicating that DCs from
autoimmune mice can increase the number and function of antigen-specific, CD25
 
  
 
CD4
 
 
 
regulatory T cells. Importantly, only 5,000 expanded CD25
 
  
 
CD4
 
  
 
BDC2.5 T cells could
block autoimmunity caused by diabetogenic T cells in NOD mice, whereas 10
 
5 
 
polyclonal,
CD25
 
  
 
CD4
 
  
 
T cells from NOD mice were inactive. When islets were examined in treated
mice, insulitis development was blocked at early (3 wk) but not later (11 wk) time points. The
expanded CD25
 
  
 
CD4
 
  
 
BDC2.5 T cells were effective even if administered 14 d after the dia-
betogenic T cells. Our data indicate that DCs can generate CD25
 
  
 
CD4
 
  
 
T cells that suppress
autoimmune disease in vivo. This might be harnessed as a new avenue for immunotherapy,
especially because CD25
 
  
 
CD4
 
  
 
regulatory cells responsive to a single autoantigen can inhibit
diabetes mediated by reactivity to multiple antigens.
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Introduction
 
Inbred nonobese diabetic (NOD) mice develop spontaneous
autoimmune diabetes that resembles human type 1 diabetes
in many respects (1–3). CD4
 
  
 
and CD8
 
  
 
T cells specific
for a number of autoantigens prove to be important in
the pathogenesis of diabetes. T cells reactive to insulin,
GAD65, and IGRP are found in NOD mice concurrent
with development of insulitis (4–6), and T cell clones specific
for these antigens can cause diabetes upon adoptive transfer.
In human diabetes, autoantibodies develop against several
autoantigens including insulin and GAD65 (7, 8). A funda-
mental issue in diabetes research is to identify mechanisms
that silence these autoimmune reactions.
Tolerance mechanisms for autoreactive T cells can be of
“intrinsic” and “extrinsic” varieties (9). Intrinsic mecha-
nisms include deletion and anergy of self-reactive T cells,
whereas extrinsic mechanisms include different regulatory
T cells that suppress other diabetogenic T cells. One type
of extrinsic suppressor is the CD25
 
  
 
CD4
 
  
 
T cell, with an
important source being the thymus (10, 11). Suppressor or
regulatory T cells maintain tolerance to self-antigens (12–15).
The transcription factor, FoxP3, is important for the devel-
opment of CD25
 
  
 
CD4
 
  
 
T regulatory cells (16–18), and
children who are born with defective FoxP3 rapidly develop
autoimmunity including diabetes (19, 20). In NOD mice,
CD25
 
  
 
CD4
 
  
 
regulatory T cells inhibit diabetes develop-
ment (21–23), making this extrinsic tolerance mechanism
an attractive target to develop antigen-specific therapies for
autoimmune disease.
In vitro, CD25
 
  
 
CD4
 
  
 
T cells will suppress the prolifer-
ative or cytokine responses of naive CD25
 
  
 
CD4
 
  
 
T cells
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(24, 25). However, the CD25
 
  
 
CD4
 
  
 
T cells are them-
selves unable to proliferate when stimulated by most types
of APCs, although proliferation does occur if the TCR is
ligated in the presence of high doses of IL-2 (24, 25). Re-
cently, it was discovered that DCs can expand antigen-spe-
cific CD25
 
  
 
CD4
 
  
 
T cells, and the latter have increased
suppressive activity (26). The observed ability of CD25
 
 
 
CD4
 
  
 
T cells to expand in a number of experimental sys-
tems in mice may well be initiated by antigen-presenting
DCs (27–31). In an experimental model of multiple sclero-
sis mediated by transgenic T cells specific to myelin basic
protein, CD25
 
  
 
CD4
 
  
 
T cells specific for this antigen
showed better suppression of disease than CD25
 
  
 
CD4
 
  
 
T
cells with TCRs specific for other antigens (32). These
findings suggest that one can use antigen-specific T cells,
rather than polyclonal populations, to suppress autoimmu-
nity. However, it has not been determined if CD25
 
 
 
CD4
 
  
 
T cells of one specificity can suppress autoimmunity
caused by T cell responses to many autoantigens, particu-
larly a spontaneous disease like diabetes in NOD mice.
The capacity of DCs to expand antigen-specific CD25
 
 
 
CD4
 
  
 
T cells now makes it possible to address these is-
sues. We used a CD4
 
  
 
TCR transgenic line that is known
to be diabetogenic, the BDC2.5 T cell (33). Despite re-
ports of defects in both CD25
 
  
 
CD4
 
  
 
regulatory T cells
and DCs in NOD mice (21, 34–36), we find that both
populations can interact productively. As a result, we have
used DCs from NOD mice to expand CD25
 
  
 
CD4
 
 
 
BDC2.5 T cells reactive to a natural pancreatic islet 
 
  
 
cell
antigen. We will show that these antigen-specific T cells
are potent inhibitors of autoimmunity mediated by au-
toreactive T cells of many specificities, whereas antigen-
nonselected populations from NOD mice have no detect-
able activity at 20-fold higher doses. This suggests a relevant
physiologic as well as therapeutic role for DCs in expand-
ing CD25
 
  
 
CD4
 
  
 
suppression in an antigen- and disease-
specific manner.
 
Materials and Methods
 
Mice.
 
NOD and NOD.scid (both I-A
 
g7
 
) mice were pur-
chased from The Jackson Laboratory. BDC2.5 TCR transgenic
mice on the NOD genetic background were provided by D.
Mathis and C. Benoist (Joslin Diabetes Center, Boston, MA).
Specific pathogen-free mice of both sexes were used at 5–12 wk
of age according to institutional guidelines. Protocols were ap-
proved by the Institutional Animal Care and Use Committee at
Rockefeller University.
 
Antibodies.
 
mAbs for MHC class II (TIB120), B220
(TIB146), CD8 (TIB211), CD4 (GK1.5), CD3 (145-2C11), and
HSA (J11d) were from American Type Culture Collection.
FITC-conjugated anti-CD25 (7D4), I-A
 
g7 
 
(OX-6), Gr1 (RB6-
8C5), CD11c (HL3) and CD4 (H129.19), CD86 (GL1), biotinyl-
ated anti-CD25 (7D4) and mouse IgG2b, APC anti-CD11c
(HL3), CD62L (MEL-14), CD25 (PC61) and CD4 (RM4-5),
and PE-streptavidin were from BD Biosciences. Purified antibody
to CD3 (145-2C11), CD49b/Pan NK cells (DX5), CD16/CD32
(2.4G2), and control rat IgG were also from BD Biosciences. We
purchased biotin goat anti–glucocorticoid-induced TNF receptor
(GITR) from R&D Systems. A hybridoma expressing the anti-
clonotype antibody specific for the BDC2.5 TCR (
 
 
 
BDC) was
provided by O. Kanagawa (Washington University, St. Louis,
MO), and the antibody was purified and biotinylated.
 
Bone Marrow–derived DCs.
 
These were prepared with GM-
CSF as previously described (26, 37). DCs were isolated from nor-
moglycemic NOD males. On day 5, LPS (Sigma-Aldrich) was
added at 50 ng ml
 
 
 
1 
 
for 
 
 
 
16 h. On day 6, cells were collected and
the more mature Grl
 
  
 
CD86
 
  
 
cells were purified with FITC and
PE magnetic microbeads (Miltenyi Biotec) as previously described
(26) and irradiated with 15 Gy before use as APCs.
 
Proliferation Assays and Expansion.
 
As previously described
(26), spleen and lymph node cell suspensions were enriched for
CD4
 
  
 
cells by panning and were sorted on a FACS Vantage™
(BD Biosciences) into CD25
 
  
 
CD4
 
  
 
and CD25
 
  
 
CD4
 
  
 
popula-
tions (
 
 
 
95 and 
 
 
 
97% pure). 10
 
4 
 
T cells from BDC2.5 or NOD
mice were cultured for 3 d with the indicated number of DCs
and a mimetope peptide (termed 1040–55; 30–100 ng ml
 
 
 
1
 
) hav-
ing the sequence RVRPLWVRME (38), or with purified anti-
CD3 antibody (0.3–1 
 
 
 
g ml
 
 
 
1
 
). RHu IL-2 (Chiron Corp.) was
added where indicated in Fig. 1 and with cultured CD25
 
  
 
cells in
Fig. 2 at 100 U ml
 
 
 
1
 
. All CD25
 
  
 
CD4
 
  
 
T cell expansions for in
vivo injection were performed with IL-2 in the cultures. To as-
sess suppression by CD25
 
  
 
CD4
 
  
 
T cells, 5 
 
  
 
10
 
4 
 
whole NOD
spleen cells irradiated with 15 Gy were used to stimulate mixtures
of 10
 
4 
 
CD25
 
  
 
CD4
 
  
 
and the indicated number of CD25
 
  
 
CD4
 
 
 
T cells from BDC2.5 or NOD mice. If DC-expanded CD25
 
 
 
CD4
 
  
 
T cells were used, CD11c
 
  
 
cells were removed using mag-
netic microbeads (Miltenyi Biotec) after harvesting the cells on
days 5–7. [
 
3
 
H]thymidine uptake (1 
 
 
 
Ci/well; PerkinElmer) by
proliferating lymphocytes was measured at 60–72 h. For in vivo
proliferation, CD25
 
  
 
CD4
 
  
 
and CD25
 
  
 
CD4
 
  
 
cells were puri-
fied by flow cytometry and labeled with 5 
 
 
 
M carboxyfluores-
cein diacetate succinimidyl ester (CFSE; Molecular Probes). 3.3 
 
 
 
10
 
5 
 
T cells were injected i.v. into NOD recipients. 1 d later, 2 
 
 
 
10
 
5 
 
BDC peptide–pulsed or –unpulsed, LPS-matured bone mar-
row DCs were injected s.c. in each paw. 3 d after DCs were in-
jected, lymph nodes were collected and cells were stained with
CD4 and BDC2.5 clonotype antibody, and the level of CFSE
staining was determined by flow cytometry.
 
Diabetes Experiments.
 
Diabetes was induced in NOD.
BDC2.5 mice with one dose of cyclophosphamide (Sigma-
Aldrich) at 200 
 
 
 
g/g in PBS. 3 d later, mice were injected with
PBS or 5 
 
  
 
10
 
5 
 
CD25
 
  
 
CD4
 
  
 
or CD25
 
  
 
CD4
 
  
 
T cells, which
had been expanded with DCs and BDC peptide in vitro for 5–7 d.
In separate experiments, diabetes was transferred to 5–9-wk-old
NOD.scid mice with 3–10 
 
  
 
10
 
6 
 
spleen cells (given i.v.) from
female diabetic NOD mice. At the same time (or later where
indicated), the indicated numbers of purified CD25
 
  
 
CD4
 
  
 
or
CD25
 
  
 
CD4
 
  
 
T cells, which had been expanded with DCs,
BDC peptide, and IL-2 in vitro for 5–7 d, were also given i.v.
For all diabetes experiments, development of diabetes was moni-
tored with chemstrips (Roche Applied Science), which detect
urine glucose above 150 mg dL
 
 
 
1
 
. A mouse was considered dia-
betic on the first of three consecutive readings of high urine glu-
cose. Due to a high incidence of thymoma development in
NOD.scids at 
 
 
 
20 wk of age, diabetes was monitored only until
the mice were 18 wk old. Statistics were calculated using the
Mann-Whitney U test.
 
Histological Analysis.
 
Pancreas tissue was fixed in Bouin’s so-
lution and paraffin-embedded sections were stained with hema-
toxylin and eosin. Tissue cuts were made 100 microns apart to
avoid counting any islets twice. Insulitis was assessed for each is- 
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let, and scored as 0, no insulitis; 1, peri-insulitis; 2, 
 
 
 
70% infil-
trated; and 3,  70% infiltrated.
Results
DCs Expand CD25  CD4  T Cells from Autoimmune
NOD Mice. We tested the ability of autoantigen-specific
CD25  CD4  T cells to expand in response to DCs. We
chose an autoreactive T cell that responds to a natural au-
toantigen and is diabetogenic. CD4  T cells from BDC2.5
TCR transgenic NOD mice respond to a protein expressed
by islet   cells (33, 39). Although the   cell autoantigen
remains to be identified, a series of mimetope peptides
have been uncovered, which also stimulate proliferation of
BDC2.5 T cells (38). We used one of these mimetope pep-
tides as antigen, which will be referred to as BDC peptide.
This particular mimetope peptide has a high functional af-
finity (low EC50) and also is recognized by a small fraction
of T cells from nontransgenic NOD mice (38).
We recently found that CD25  CD4  cells from nonau-
toimmune mice will grow in response to antigen-bearing
DCs, particularly mature CD86  bone marrow–derived
DCs (26). Therefore, we prepared  95% pure CD25 
CD4  BDC2.5 T cells and NOD bone marrow DCs (from
male normoglycemic mice). In agreement with previous
data on the DCs from NOD mice (35, 40), there was a
lower (approximately twofold) frequency of CD86 high
DCs relative to other strains like C57Bl/6. However, we
used magnetic beads to enrich the smaller subset of CD86 
NOD DCs. These expressed high levels of CD86, compa-
rable to other strains (Fig. 1 A and not depicted).
When we cultured BDC2.5 CD25  CD4  T cells with
NOD CD86  DCs pulsed with BDC peptide, the T cells
proliferated by day 3 (Fig. 1 B). Proliferation also took
place in response to CD86  DCs pulsed with BDC pep-
tide, but it was more limited (not depicted). CD25  CD4 
cells likewise proliferated to DCs with BDC peptide, but
the addition of IL-2 did not significantly change prolifera-
tive responses. CD25  CD4  T cells cultured with DCs
and IL-2 (but not with BDC peptide) also showed signifi-
cant proliferation, as was evident with ovalbumin-specific
CD25  CD4  T cells (26), but the combination of IL-2
and BDC peptide with DCs was more effective, resulting
in higher [3H]thymidine incorporation than with CD25 
CD4  cells. Previously, groups have observed some prolif-
eration of CD25   CD4   T cells cultured with spleen
APCs, a TCR stimulus, and IL-2 (24, 25). We found that
these conditions (BDC2.5 T cells, spleen APCs, BDC pep-
Figure 1. NOD DCs induce growth of CD25  CD4  T
cells from NOD.BDC2.5 or NOD mice. (A) In vitro–
derived NOD DCs were stained with antibodies specific
for CD86 and MHC class II before (left) and after (right)
magnetic bead enrichment of CD86  cells. (B) CD25 
CD4  or CD25  CD4  T cells sorted from BDC2.5 TCR
transgenic mice were cultured with CD86  NOD DCs
with and without 30 ng ml 1 BDC peptide and IL-2. In
the same experiment, NOD spleen cells were used with
IL-2, with and without BDC peptide (right). A 12-h
[3H]thymidine pulse was given on day 3. (C) Same as B,
but the dose of BDC peptide was 100 ng ml 1 and the fold
increase in T cell numbers was monitored by counting on
days 3, 5, and 7. (D) CD25  or CD25  CD4  T cells were
isolated from NOD mice and cultured with NOD CD86 
DCs, with and without anti-CD3 and IL-2 as indicated.
Proliferation was determined by [3H]thymidine incorporation
on day 3. (E) As in D, but cells were counted on days 3, 5,
and 7, and the fold increase in cell numbers was calculated.
One result of at least three similar experiments is shown.DC-expanded, Autoantigen-specific, CD25  CD4  T Cells Suppress Diabetes 1470
tide, and IL-2) induced at least 3.5-fold lower proliferation
than with DCs under the same conditions (Fig. 1 B, right).
Using the condition in Fig. 1 B, which gave the highest
level of proliferation, we tested the ability of the cells to
expand during a 1-wk culture. Relative to the number of
cells placed into culture, there was a 5–10-fold expansion
in the number of recovered T cells from cultures of
CD25  CD4  T cells, DCs, and BDC peptide with and
without IL-2 at 5 d. CD25  and CD25  CD4  T cells ex-
panded similarly up to day 5, but only the latter continued
to expand up to day 7 (Fig. 1 C). Thus, CD25  CD4  T
cells from BDC2.5 transgenic mice can grow in response to
DCs in an antigen-specific manner, in much the same way
as recently reported for ovalbumin-specific T cells (26).
To show that nontransgenic regulatory T cells from au-
toimmune NOD mice were capable of proliferation and
expansion with DCs, we sorted NOD CD25  CD4  T
cells and stimulated them with NOD CD86  DCs and
anti-CD3. With this polyclonal stimulus, DCs were able to
induce DNA synthesis and expansion of NOD CD25 
CD4  T cells (Fig. 1, D and E). The T cells also prolifer-
ated when cultured with DCs and IL-2 in the absence of a
TCR stimulus, but IL-2, DCs, and anti-CD3 synergized to
induce very high levels of DNA synthesis and expansion of
cell numbers,  10-fold by 5 d. In contrast, NOD CD25 
CD4  T cells cultured without DCs but with IL-2 with or
without anti-CD3, gave only 2   103 or 7   103 cpm of
DNA synthesis, respectively. Control NOD CD25  CD4 
T cells given DCs and anti-CD3 with or without IL-2,
showed both proliferation and expansion. These results in-
dicate that both DCs and T cells (either BDC2.5 or non-
transgenic) from autoimmune NOD mice can interact to
significantly expand CD25  CD4  regulatory T cells.
Phenotype of DC-expanded CD25  CD4  T Cells. To
identify BDC2.5-specific T cells after DC-mediated expan-
sion, cultures were stained with an mAb specific for the
BDC2.5 TCR. Approximately 80% of freshly isolated or
DC plus IL-2–expanded BDC2.5 CD25  CD4  T cells ex-
pressed high levels of this clonotype (Fig. 2, left). In con-
trast, when BDC2.5 CD25  CD4  T cells were stimulated
with DCs, IL-2, and anti-CD3, the level of clonotype ex-
pression was much lower than on cells expanded with DCs
presenting BDC peptide. As expected, DC plus anti-CD3–
stimulated NOD CD25  CD4  T cells did not express sig-
nificant levels of BDC clonotype compared with isotype
controls (Fig. 2, left). Because T cells expressing a trans-
genic TCR also can express endogenous TCR-  chains,
we checked expression of two different endogenous TCR
alphas (V 2 and V 8.3), and found similar percentages of
cells expressing endogenous V alphas before and after DC-
BDC peptide stimulation (Fig. 2, middle, and not de-
picted). Interestingly, the level of V 2 expressed on
CD25  CD4  T cells expanded with CD3 was lower than
freshly isolated cells or those expanded with BDC peptide.
This suggests that anti-CD3 causes a down-regulation of
TCR expression that is not specific to the BDC2.5 TCR.
For comparison, clonotype and V 2 expression on CD25 
CD4  T cells expanded under the same conditions is shown,
and down-regulation of either clonotype or V 2 expres-
sion is not as severe as with CD25  CD4  T cells. This data
indicates that in contrast to T cells expanded with DCs plus
anti-CD3, BDC2.5 T cells expanded with DCs plus BDC
peptide express much higher levels of TCR on their cell
surfaces.
To characterize the DC-expanded regulatory cells, these
cells were stained with antibodies specific for CD25,
CD62L, and GITR. The cultured CD25  CD4  T cells
maintained high levels of CD25 and GITR, and many of
the cultured CD25   CD4   T cells up-regulated both
CD25 and GITR (not depicted). The freshly isolated
BDC2.5 CD25  CD4  T cells contained  40% CD62L
low cells, and DC expansion did not significantly change
this phenotype (Fig. 2, right). In contrast, the freshly iso-
lated CD25  CD4  T cells contained only  10% CD62L
Figure 2. Phenotype of DC-
expanded T cells. Expression of
BDC2.5 clonotype (left), TCR
V 2 (middle), and CD62L
(right) on CD25   or CD25 
CD4  T cells cultured under the
conditions indicated. For the
BDC2.5 clonotype, the isotype
control peak is shown by the
dashed line. For V 2 and
CD62L, the percentage of cells
in the indicated gates is shown.
One result of at least three simi-
lar experiments is shown.Tarbell et al. 1471
low cells, and activation with DCs greatly increased the
percentage of the CD62L low cells (Fig. 2, right). IL-2 was
added to all cultured CD25  CD4  T cells in addition to
the indicated culture conditions shown in Fig. 2, but simi-
lar expression of clonotype, V 2, and CD62L was ob-
served for CD25  CD4  T cells cultured without IL-2
(not depicted). Collectively, expression of these activation
markers before and after DC stimulation is similar to that
found in nonautoimmune strains (26), indicating that DC
activation of NOD regulatory cells occurs normally.
Expansion of CD25  CD4  T Cells with DCs In Vivo.
To determine if DCs also can induce proliferation of
CD25  CD4  T cells in vivo, we purified CD25  CD4  T
cells from BDC2.5 mice, labeled them with CFSE before
injection into NOD mice, and 1 d later, we s.c. injected
mature marrow–derived DCs that had been pulsed (or not
pulsed as control) with BDC peptide. We assessed prolif-
eration 3 d later by progressive halving of the amount of
CFSE per T cell. The CD25  CD4  T cells proliferated,
with up to six divisions per cell, in the draining lymph
nodes of mice that received BDC peptide–pulsed DCs,
but not in mice that received PBS or DCs alone (Fig. 3
and not depicted). We observed similar proliferative re-
sponses with control CD25  CD4  cells, but CFSE was
not diluted in either CD25  or CD25  CD4  cells in the
distal lymph nodes of mice receiving either pulsed or un-
pulsed DCs (Fig. 3). Therefore, DCs are able to induce the
proliferation of CD25  CD4  T cells from an autoim-
mune strain in vivo.
Enhanced In Vitro Suppressive Function of DC-expanded,
CD25  CD4  T Cells. To verify that the expanded
CD25  CD4  T cells from BDC2.5 mice retained suppres-
sive function, we used a standard in vitro suppression assay.
We removed CD11c  DCs from 7-d expansion cultures
and added the T cells in different ratios to responder
CD25  CD4  T cells to measure the inhibition of CD25 
CD4  proliferation in response to BDC peptide presented
Figure 3. BDC2.5 CD25  CD4  T cells proliferate in vivo. CFSE-
labeled BDC2.5 CD25  CD4  (left) or CD25  CD4  (right) T cells were
injected into NOD mice. 1 d later, either DCs without antigen (top) or
BDC peptide–pulsed DCs (middle and bottom) were injected s.c. 3 d
after antigen delivery, the injected  1,000 CFSE-labeled clonotype  cells
from draining (top and middle) or distal (bottom) lymph nodes were
assessed for proliferation by flow cytometry, gating on CD4  lympho-
cytes. The percentages in the dividing and nondivding populations of
clonotype  cells is shown.
Figure 4. DC-expanded CD25  CD4  T cells suppress proliferation
better than unexpanded CD25  CD4  T cells. (A) CD25  CD4  T cells
from NOD.BDC2.5 mice were expanded for 7 d with irradiated NOD
DCs and BDC peptide and IL-2 as indicated. 104 freshly isolated, sorted
CD25  CD4  T cells from BDC2.5 mice were cultured with NOD
spleen cells, 30 ng/ml BDC peptide, and either freshly sorted CD25 
CD4  or the indicated DC-expanded CD25  CD4  populations, at the
ratios indicated. After 72 h, proliferation was assessed by [3H]thymidine
incorporation during a 12-h pulse. One representative result from at least
three is shown. (B) Same as A, but both CD25  and CD25  CD4  T cells
were isolated from NOD mice, and anti-CD3 was used as TCR stimulus
instead of BDC peptide in both expansion and suppression cultures. One
representative result from at least three is shown.DC-expanded, Autoantigen-specific, CD25  CD4  T Cells Suppress Diabetes 1472
by spleen APCs. Freshly isolated CD25  CD4  T cells, as
well as CD25  CD4  T cells expanded with DCs and IL-2,
were able to suppress, but only partially and at high doses,
i.e., when mixed at a 1:2 ratio with CD25  CD4  cells. In
contrast, CD25  CD4  T cells expanded with BDC pep-
tide (without or with IL-2) had stronger activity, showing
suppression even at a ratio of 1 CD25  CD4  T cell for ev-
ery 8 CD25  CD4  cells (Fig. 4 A). We also tested the sup-
pressive function of NOD CD25  CD4  T cells expanded
with DCs and anti-CD3. Again, the T cells expanded with
DCs and TCR stimulus suppressed proliferation by NOD
CD25  CD4  T cells approximately fourfold more effi-
ciently than freshly isolated CD25  CD4  T cells (Fig. 4
B). Although freshly purified NOD CD25  CD4  T cells
showed  75% suppression at a ratio of 8 responder cells for
1 CD25  CD4  T cell, NOD CD25  CD4  T cells ex-
panded with DCs and anti-CD3 (with or without IL-2)
showed similar suppression at a ratio of 32:1. Therefore, ei-
ther polyclonal or monospecific CD25  CD4  T cells from
NOD mice can be expanded with DCs and anti-CD3 or
antigen, and they show approximately fourfold enhance-
ment in suppressive function.
DC-expanded CD25  CD4  T Cells Efficiently Suppress
Diabetes In Vivo. A critical in vivo function for CD25 
CD4  T cells is the prevention of autoimmunity. There-
fore, we wanted to determine if BDC2.5 CD25  CD4  T
cells expanded in vitro with DCs and antigen could inhibit
the development of diabetes. The first model of diabetes
we used was one in which the pathogenic T cells to be
suppressed were of the same BDC2.5 specificity. As ex-
pected from previous work (41), most BDC2.5 mice on
the NOD background did not develop diabetes, but when
young BDC2.5 NOD mice were given one injection of
cyclophosphamide, diabetes developed 4–7 d later in 100%
of the mice. To suppress this diabetes induction, 3 d after
cyclophosphamide treatment, we injected BDC2.5.NOD
mice with DC-expanded CD25   CD4   T cells from
BDC2.5 mice. In two experiments, this resulted in a delay
of diabetes onset and a reduced diabetes incidence. In
contrast, injection of DC-expanded CD25  CD4  from
BDC2.5 mice had little effect on diabetes development
(Fig. 5 A). These results show that the DC-expanded sup-
pressor T cells are able to suppress autoimmunity even
when the disease is developing rapidly.
Figure 5. Expanded CD25  CD4  T cells function in vivo to suppress development of diabetes. (A) 4–6-wk-old NOD.BDC2.5 mice were given
cyclophosphamide i.p. 3 d later, either 5   105 DC-expanded CD25  CD4  T cells or CD25  CD4  cells were injected i.v. (B) NOD.scid females were
injected with 3   106 spleen cells from a diabetic NOD female and either nothing or the indicated numbers of DC-expanded CD25  CD4  T cells or
3   105 CD25  CD4  cells from BDC2.5 mice. (C) NOD.scid females were injected with either 4   105 CD25  CD4  cells from BDC2.5 mice, or
8   106 spleen cells from a diabetic NOD female and either nothing or the indicated numbers of DC-expanded CD25  CD4  T cells from BDC2.5
mice. The difference between diabetic spleen alone to diabetic spleen plus 500 CD25  CD4  cells was significant (P   0.002), as was diabetic spleen to
diabetic spleen plus 5,000 CD25  CD4  cells (P   0.002). One representative result from two experiments is shown. (D) NOD.scid females were in-
jected with 8   106 diabetic spleen cells alone or with 105 freshly isolated or DC/ CD3-expanded CD25  CD4  T cells from NOD mice. The number
of mice in each group is indicated in parentheses.Tarbell et al. 1473
We then tested a second model, injection of spleen cells
from diabetic NOD mice into NOD.scid females, because
this model is mediated by pathogenic T cells with a diverse
repertoire of TCR specificities. We injected different doses
of DC-expanded CD25  CD4  T cells from BDC2.5 mice
with 3–10    106 spleen cells from diabetic mice into
NOD.scid females. The mice receiving diabetic spleen
cells alone developed diabetes starting at 3–4 wk after in-
jection as expected (42, 43). In the first dose-response
study, the addition of 3   105, 105, or 3   104 expanded
BDC2.5 CD25  CD4  T cells to 3   106 diabetic spleen
cells completely prevented diabetes development (Fig. 5
B). In contrast, when we injected 3   105 DC-expanded
CD25  CD4  cells together with diabetic spleen cells,
there was a marked acceleration of diabetes onset when
compared with diabetic spleen cells alone. In a second
dose-response experiment, we increased the number of di-
abetic spleen cells to 8   106, and the number of expanded
CD25  CD4  T cells was titrated down further. Again
50,000 DC-expanded BDC2.5 CD25  CD4  T cells com-
pletely prevented diabetes development up to 80 d after
transfer. The addition of 5,000 of these regulatory cells also
gave a large delay in diabetes, and even 500 DC-expanded
BDC2.5 CD25  CD4  T cells showed a significant delay
in diabetes compared with those receiving spleen cells from
diabetic mice alone (Fig. 5 C). In both experiments, unex-
panded BDC2.5 CD25  T cells showed a similar ability to
block or delay diabetes development (not depicted). Three
similar experiments with both DC-expanded and -unex-
panded regulatory cells have now been performed with
similar results.
The numbers of DC-expanded autoantigen-specific
CD25  CD4  T cells necessary to delay or block diabetes
development here were much lower than the numbers of
bulk (polyclonal) NOD CD25  CD4  T cells used in
other transfer studies, i.e., at least 2–5   105 cells were
necessary to see a significant delay in diabetes development
(22, 23, 44). To establish the need for antigen-specific T
cells in disease suppression, and to confirm in our system
that DC stimulation alone was not sufficient for in vivo
suppression, NOD CD25  CD4  T cells expanded with
DCs plus anti-CD3 were transferred to NOD.scid mice
along with spleen cells from diabetic mice. Even 105 poly-
clonal NOD CD25  CD4  T cells, either freshly isolated
or anti-CD3/DC expanded, were unable to delay diabetes
(Fig. 5 D). In addition, freshly isolated BDC2.5 regulatory
T cells could also block diabetes development with similar
cell numbers as the DC-expanded T cells (not depicted),
suggesting that antigen specificity, rather than expansion
with BDC peptide stimulation, is the most critical variable
for suppression of diabetes in vivo. Therefore, autoanti-
gen-specific DC-expanded CD25  CD4  T cells function
efficiently in vivo to suppress autoimmunity mediated by
autoreactive T cells.
Figure 6. Protected mice have
lymphocytic infiltrates in the pan-
creas. (A) Pancreata from mice that
did not develop diabetes by day
80 after transfer in the experi-
ment shown in Fig. 5 C were
scored for insulitis. 150 islets
from 5 mice were scored from
the group that received 50,000
DC-expanded BDC CD25 
CD4  T cells, and 48 islets from
2 mice were scored from the
group that received 5,000 cells.
(B) Representative fields for a
mouse from the group that re-
ceived 5,000 (top) or 50,000
(bottom) suppressor T cells. Large
field is 5 ; inset is 20 . (C) In a
separate experiment, pancreata
from mice 28 d after transfer
were scored for insulitis. At least
50 islets from 2–3 mice were
scored from each group.DC-expanded, Autoantigen-specific, CD25  CD4  T Cells Suppress Diabetes 1474
Mice Receiving Autoantigen-specific CD25  CD4  T Cells
Can Develop Insulitis. To determine at which stage disease
was blocked in NOD.scid mice protected from diabetes by
small numbers of BDC2.5-specific CD25  CD4  T cells,
pancreata were isolated from those mice that still had nor-
mal glucose levels at the end of the experiment shown in
Fig. 5 C (80 d after transfer). Insulitis was scored from he-
matoxylin and eosin–stained sections. The mice from the
groups that received 5,000 or 50,000 BDC2.5-specific
CD25  CD4  T cells (the latter group were all diabetes
free), had lymphocytic infiltrates in half of the islets scored
(Fig. 6 A). A representative field from both protected
groups is shown (Fig. 6 B). In a separate transfer experi-
ment, pancreata were isolated from mice earlier on, at 23
or 28 d after transfer of the diabetogenic and regulatory
cells. At this earlier time point, the mice that had received
only the diabetogenic cells had some insulitis, but those
that had also received BDC2.5 regulatory cells lacked lym-
phocytic infiltrate in the islets (Fig. 6 C). This indicates that
protected mice can progress past the initiation of islet in-
flammation, checkpoint I, but the kinetics of insulitis is
slower than in the absence of regulatory cells.
Autoantigen-specific CD25  CD4  T Cells Can Still Regu-
late When Given after Diabetogenic Cells. One feature of
the NOD.scid system is that T cells, when injected into a
lymphopenic host, undergo antigen-independent, homeo-
static proliferation. To lessen the effect of such prolif-
eration on the CD25  CD4  T cells, the latter were in-
jected after the diabetogenic spleen cells. Even when given
11 d after the diabetogenic cells, as few as 12,000 DC-
expanded, BDC2.5 CD25  CD4  T cells prevented diabetes
development (Fig. 7 A). When given 15 d after diabeto-
genic cells, 104 cells significantly delay diabetes (Fig. 7 B). At
these time points, by FACS® staining for CD4  cells, we
showed that lymphocytes from the diabetic mice had re-
populated the lymphoid organs, and even entered the pan-
creas (not depicted). Therefore, CD25  CD4  T cells can
block diabetes even after the diabetogenic cells have been
given time to occupy the lymphoid compartments, and
initiate diabetes pathogenesis. Further studies will be needed
to check the capacity of DC-expanded, antigen-specific
CD25  CD4  T cells to suppress disease under nonho-
meostatic conditions.
Discussion
Despite the importance of T cell responses to islet au-
toantigens, currently no diabetogenic CD4  TCR trans-
genic specific for a known   cell protein is available. Three
islet-reactive, CD4  transgenic lines exist. GAD65-reac-
tive, G286 mice have nondiabetogenic T cells (45). A sec-
ond 4.1 transgenic is generally stimulated with whole islets
as the source of antigen (46). The third, BDC2.5, is specific
for an as yet unknown antigen expressed by   cells in pan-
creatic islets, but this antigen can be replaced by peptide
mimetopes, providing an opportunity to test the suppres-
sive capacity of antigen-specific BDC2.5 CD25  CD4  T
cells on the development of diabetes (38). The preparation
of significant numbers of antigen-specific suppressor T cells
has been held back at least in part because of a lack of infor-
mation on APC requirements. This difficulty can now be
addressed because DCs will expand CD25  CD4  regula-
tory T cells and if anything, increase their function per cell
(26). We have now tested these systems in the NOD
model of spontaneous autoimmune diabetes. Our results
contribute to three issues relating to CD25  CD4  suppres-
sor T cell function in autoimmune disease.
Both DCs and CD25  CD4  T Cells from the NOD Au-
toimmune Strain Have the Potential to Generate Suppressive
Function. The capacity of DCs to expand functional
CD25  CD4  suppressor T cells was to some extent unex-
pected, given reports of defects in both CD25  CD4  T
cells (21, 36) and DCs (34) in NOD mice. We find that the
yield of CD86 high DCs in our bone marrow cultures
from NOD mice is twofold less than that observed with
bone marrow from C57BL/6 mice, suggesting that sponta-
neous maturation of DCs in NOD cultures is to some ex-
Figure 7. BDC2.5 CD25  CD4  T cells can still regulate diabetes
when given after diabetogenic cells. (A) NOD.scid females were injected
with 8   106 diabetic spleen cells and 11 d later were injected with either
PBS or the indicated number of DC-expanded CD25  CD4  T cells
from BDC2.5 mice. The difference between diabetic spleen alone to diabetic
spleen plus 105 or 104 DC-expanded CD25  CD4  cells was significant
(P   0.002). (B) As in A, except 107 diabetic spleen cells were added 15 d
before the indicated number of DC-expanded CD25  CD4  T cells
from BDC2.5 mice. The p-value for diabetic spleen alone versus adding
105 BDC2.5 regulatory T cells is 0.055 and versus adding 104 BDC2.5
regulatory T cells is 0.0595. The number of mice in each group is indi-
cated in parentheses.Tarbell et al. 1475
tent reduced. Because mature DCs are the most potent and
perhaps critical APCs for expanding CD25  CD4  T cells
(26), it is possible that DC maturation in NOD mice is less
efficient in situ leading to a reduction in the number and
function of regulatory CD25  CD4  T cells (34, 40). Fur-
ther studies will address the ability of DCs isolated from
NOD mice at different stages of diabetes pathogenesis to
allow expansion of CD25  CD4  cells.
Autoimmunity may develop as a result of defects in either
the initial number of CD25  CD4  T cells produced in the
thymus, or the homeostasis and function of these cells in the
periphery. Although some groups have reported a decrease
in the numbers of CD25  CD4  T cells in NOD mice as
compared with other strains, others report normal numbers
in lymphoid organs of prediabetic mice (21, 23, 47). Lower
numbers of CD25  CD4  T cells also have been reported in
patients with type I diabetes (48). Nevertheless, the addition
of polyclonal populations of CD25  CD4  T cells can delay
onset and decrease diabetes incidence, although the number
of cells required is relatively high, on the order of at least
0.5   106 per mouse (22, 23). In our studies, 105 CD25  CD4 
T cells from NOD mice, even when expanded by DCs and
anti-CD3 in culture, are inactive in suppressing diabetes, in-
dicating that the antigen specificity of BDC2.5 regulatory T
cells is critical. We do know that after DC expansion, almost
all of the BDC CD25  CD4  T cells express high levels of
the BDC TCR. CD25  CD4  TCR transgenic T cells can
express second TCRs due to endogenous rearrangements of
TCR-  genes (49, 50), making it possible that the expanded
BDC2.5 T cells have additional reactivities with pancreatic
autoantigens. In any case, it is unlikely that these second
TCRs are critical for the observed disease-suppressive prop-
erties of expanded BDC2.5 T cells because the polyclonal
repertoire of NOD T cells has so little activity.
In normal female NOD mice, there is a 4–8-wk gap be-
tween the beginning of lymphocyte infiltration of the pan-
creas, which starts between 3 and 8 wk of age (called
checkpoint I), and overt destruction of the islets resulting
in glucose dysregulation, which starts between 12 and 20
wk of age (called checkpoint II; references 1 and 51).
When CD25  CD4  T cells are reduced in NOD mice as a
result of genetic defects, the transition from initiation of in-
sulitis to overt diabetes is rapid (21). This suggests that
CD25  CD4  T cells might be important for controlling
checkpoint II. Consistent with this, CD25  CD4  T cells
from 8-wk-old NOD mice have recently been shown to
suppress more efficiently than those from 16-wk-old mice
(44). Our data showing insulitis in mice protected from di-
abetes development by BDC2.5 CD25  CD4  T cells is
consistent with regulatory cells maintaining a benign pan-
creatic inflammation. However, because insulitis appears
later in mice that received suppressor cells, these cells also
appear to delay the initial inflammation of the islets.
DCs Control the Peripheral Expansion of CD25  CD4  T
Suppressor T Cells. Our results introduce a potentially crit-
ical role played by DCs in controlling autoreactive sup-
pressor T cell function in the periphery. The function of
CD25  CD4  T cells in regulating autoimmunity is well es-
tablished and dramatized by the rapid development of au-
toimmunity including diabetes in humans and mice that
lack the FoxP3 factor, which is required for the develop-
ment of these T cells and possibly not other elements of the
immune system (17, 19). However, APCs have not been
studied. We now find that DCs expand disease-suppressive
CD25  CD4  T cells and that the expanded cells are more
efficient suppressors of autoreactivity than their freshly iso-
lated counterparts, at least in vitro. Expansion of these regu-
latory cells also occurs with DCs and IL-2 in the absence of
antigen, but then, suppression in vitro is comparable to
freshly isolated, nonexpanded CD25  CD4  T cells. There-
fore, stimulation through the TCR of CD25  CD4  regu-
latory cells increases their suppressive potency in culture by
approximately fourfold. When one takes into account the
5–10-fold increase in cell numbers, the total increase in
overall activity is at least 20-fold. The peripheral expansion
of regulatory cells with antigen and DCs described here
might be important for preventing autoimmunity in normal
individuals by maintaining proper levels of CD25  CD4  T
cells. We are pursuing this suggestion by targeting autoanti-
gens directly to DCs in situ and then observing the conse-
quences for T cells and autoimmune disease in situ.
CD25  CD4  Suppressor T Cells of One Specificity Can
Control Autoimmune Disease Directed to Many Specificities.
The third issue, which is a major focus of this paper, is that
CD25  CD4  T cells expanded with DCs and a single anti-
gen can suppress diabetes in vivo and with very low num-
bers of cells (Fig. 5) compared with polyclonal CD25 
CD4  T cells from NOD mice (22, 23, 44). Adoptive
transfer of 5,000 fresh or DC-expanded BDC2.5 regulatory
T cells is able to suppress disease induced by a polyclonal
population of T cells from diabetic mice, whereas 100,000
anti-CD3–expanded NOD CD25  CD4  T cells are inac-
tive. This may occur because the regulatory T cells are spe-
cific for an autoantigen expressed in   cells, the same tissue
for which the pathogenic T cells are also specific. This in
turn may allow the BDC2.5 CD25  CD4  T cells to home
to or function in the islets and/or pancreatic lymph node
more efficiently than NOD CD25  CD4  T cells of other
specificities. Because a nonislet-specific TCR transgenic
restricted to I-Ag7 has not been developed, it is not possible
to assess the ability of such “control” T cells to block dia-
betes. Antigen-nonspecific regulation has been shown in
vitro by using CD25  and CD25  CD4  T cells from dif-
ferent TCR transgenic mice. As long as the CD25  CD4 
T cells are provided with their cognate antigen, they will
suppress T cells of another specificity (24, 52). In our sys-
tem, because CD25  CD4  T cells of one specificity can
block the diabetes-inducing T cells of many specificities,
this suggests that in vivo, regulation by CD25  CD4  T
cells extends to other   cell antigens, not just those specifi-
cally recognized by the CD25  CD4  suppressor cell. This
might involve local cytokine secretion (53), or the global
blocking of APC function within the islets themselves or
possibly in pancreatic lymph nodes.DC-expanded, Autoantigen-specific, CD25  CD4  T Cells Suppress Diabetes 1476
Our findings suggest that DCs might be harnessed to de-
velop new antigen-specific immunotherapies for autoimmu-
nity based on CD25  CD4  suppressor T cells. For example,
islet autoantigen–specific regulatory cells could be expanded
ex vivo by culturing CD25  CD4  T cells from recently di-
agnosed diabetics with DCs loaded with islet antigens de-
rived either from islet tissue or peptide mixtures of identified
autoantigens. New assays of T cell responses in diabetic pa-
tients are being developed, which should be helpful for de-
signing peptide mixtures (54), especially because some evi-
dence suggests that CD25  CD4  effector populations have
a similar TCR repertoire as CD25  CD4  regulatory popu-
lations (32). The advantage of directing therapy to specific
antigens is the avoidance of generalized immunosuppression,
but the potential disadvantage is the possibility that generat-
ing tolerance to one antigen may not block a disease medi-
ated by T cells with many specificities, as in NOD mice (7).
However, it is now evident that DC- and antigen-expanded
CD25  CD4  T cells of one specificity are potent at pre-
venting diabetes pathogenesis mediated by NOD T cells.
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